AIMS
6 mercaptopurine (6MP) is the mainstay chemotherapy for acute
lymphoblastic leukaemia (ALL) and is conventionally available as 50 mg
tablets. This study aimed to evaluate the
bioequivalence of a new 6MP
Powder for Oral Suspension (PFOS) intended for paediatric use.
Additionally, a virtual study with the obtained data was planned for
determining a dose of the PFOS that matches tablet exposures and to
confirm optimal drug levels in pediatrics.